GHENT, Belgium, 28 May 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has initiated a double-blind, randomized, placebo-controlled multiple dose Phase Ib study for its novel anti-thrombotic that selectively targets von Willebrand (vWF) factor. The study is being conducted in patients with stable angina undergoing percutaneous coronary intervention (PCI). The Company also provides today its first business update in compliance with the EU transparency directive summarising material events and Ablynx's financial position for the first quarter of 2008.
